Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

1.3K
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.3K
Atypical Pneumonia01:14

Atypical Pneumonia

47
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
47
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.2K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.2K
The pathophysiology of pneumonia involves the following steps:
4.2K
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

4.0K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
4.0K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?

American journal of respiratory and critical care medicine·2020
Same author

Biomarkers in the ICU: less is more? No.

Intensive care medicine·2020
Same author

Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020).

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome.

EBioMedicine·2020
Same author

Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia.

Annals of the American Thoracic Society·2020
Same author

Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience.

Respiratory medicine·2020
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Apr 5, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.8K

Neumonía adquirida en la Comunidad

Elena Prina1, Otavio T Ranzani2, Antoni Torres1

  • 1Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut D'investigacions August Pi I Sunyer (IDIBAPS), Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.

Lancet (London, England)
|August 17, 2015
PubMed
Resumen
Este resumen es generado por máquina.

El tratamiento eficaz de la neumonía adquirida en la comunidad requiere un tratamiento antibiótico individualizado y un seguimiento minucioso. Este enfoque tiene como objetivo reducir la resistencia a los antibióticos y mejorar los resultados de los pacientes, haciendo hincapié en los cambios orales oportunos y en los criterios de estabilidad clínica.

Más Videos Relacionados

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.6K

Videos de Experimentos Relacionados

Last Updated: Apr 5, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.8K
Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

24.2K
Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
08:25

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling

Published on: April 7, 2015

9.6K

Área de la Ciencia:

  • Enfermedades infecciosas
  • Pulmonología
  • Farmacología

Sus antecedentes:

  • La neumonía adquirida en la comunidad (CAP) presenta una mortalidad, una morbilidad y una carga económica significativas en todo el mundo.
  • La selección empírica de antibióticos es fundamental para la gestión de la PAC, pero el uso indebido contribuye a la resistencia y los efectos adversos.

Objetivo del estudio:

  • Esbozar los principios para un tratamiento antibiótico eficaz e individualizado de la PAC.
  • Para resaltar la importancia del seguimiento, el cambio oral temprano y la administración de antibióticos.
  • Discutir nuevos enfoques de diagnóstico y las implicaciones a largo plazo de la PAC.

Principales métodos:

  • Revisión de las estrategias actuales de tratamiento de la neumonía adquirida en la comunidad.
  • Discusión de los principios de administración de antibióticos y los criterios de estabilidad clínica.
  • Exploración de tecnologías de diagnóstico emergentes como el ultrasonido pulmonar y los métodos moleculares.

Principales resultados:

  • El uso optimizado de antibióticos puede mitigar la resistencia y los efectos secundarios.
  • La transición temprana a antibióticos orales y la duración del tratamiento adaptado son clave.
  • Los diagnósticos avanzados ofrecen el potencial para un diagnóstico más rápido y preciso.

Conclusiones:

  • Las estrategias de antibióticos individualizadas y basadas en la evidencia son esenciales para la gestión de la PAC.
  • El seguimiento y la administración cercanos de los pacientes son cruciales para obtener resultados óptimos.
  • Se justifica una mayor investigación sobre las secuelas y la gestión a largo plazo de la PAC.